- Report
- March 2025
- 89 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- January 2025
- 182 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- January 2024
- 140 Pages
Global
From €4056EUR$4,250USD£3,398GBP
The Disruptive Behavior Disorder Drug market is a subset of the Central Nervous System Drugs market. It includes drugs used to treat Attention Deficit Hyperactivity Disorder (ADHD), Oppositional Defiant Disorder (ODD), and Conduct Disorder (CD). These drugs are typically stimulants, such as methylphenidate and amphetamine, or non-stimulants, such as atomoxetine and guanfacine. They are used to reduce symptoms of hyperactivity, impulsivity, and inattention, as well as aggression and defiance.
The Disruptive Behavior Disorder Drug market is highly competitive, with many companies offering similar products. Major players include Shire, Novartis, Eli Lilly, Pfizer, and Johnson & Johnson. Other companies in the market include Actavis, Teva Pharmaceuticals, and Impax Laboratories. Show Less Read more